Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Date:5/12/2008

rd-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "preliminary"; "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with the development of MDX-1100, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... MOUNTAIN VIEW, Calif., Feb. 28, 2011 VIVUS, ... to the development and commercialization of novel therapeutic products, today ... and year ended December 31, 2010. ... development program, we successfully completed the two-year SEQUEL study, an ...
... The staffs of Chiltern International Limited (Chiltern), a global ... 25 year mark of their successful collaboration in Drug ... have worked together using a validated and regulatory accepted ... assessment of drug phototoxicity. The history of this collaboration ...
Cached Medicine Technology:VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 2VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 3VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 4VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 5VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 6VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 7Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 2Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 3
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
(Date:7/9/2014)... have been linked to an emerging fungal disease ... Institute for Mathematical and Biological Synthesis (NIMBioS) shows ... , In a series of mathematical models, researchers ... internal organs in frogs, could cause extinction of ... exposed to the virus every few years, a ...
(Date:7/9/2014)... flatulence and have a reputation for being highly toxic, but ... now being being found to offer potential health benefits in ... and dementia. A new compound (AP39), designed and made at ... therapies, by targeting delivery of very small amounts of the ... , Scientists in Exeter have already found that the compound ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... A specific gene is particularly frequently involved in the development ... sequences of genetic material on the X and Y chromosome ... children. These gene regulators determine how frequently a gene is ... mutation of one regulatory sequence of the SHOX gene is ...
... Small babies at risk for osteoporosis decades later, study finds ... born preterm with a very low birth weight have significantly ... full term, a Finnish study has found. , The researchers ... 27, who were born preterm with very low birth weight. ...
... , , FRANKLIN, Mass., Aug. 25 ... on innovative cardiac and vascular medical device-based technologies, today announced ... its RenalGuard System(TM) has been published, in advance of the ... - September 2, 2009 in Barcelona, Spain, on the ESC ...
... , CLEVELAND, Aug. 25 As part of ... Cleveland is proud to have been recognized as part of the ... International Business Awards. The IBA selected Jani-King,s entry as the ... and individuals from 27 countries, including first-time winners from Japan, New ...
... Aug. 25 Moszkito(R), the name in "healthy flip-flops," is ... include closed footwear for Fall 2009. The 4 new styles, ... 16 mm arch support. In black and brown Italian Waxed ... , Based in Scottsdale, Arizona, Moszkito has established ...
... , NEW YORK, Aug. 25 Impelsys ( ... leader in electronic content delivery solutions, today announced that the American ... www.i p u blishcentral.com ), an ... monetize traditional print content through electronic channels. , ...
Cached Medicine News:Health News:Not only the gene itself, its abnormal regulation can also trigger short stature 2Health News:Not only the gene itself, its abnormal regulation can also trigger short stature 3Health News:PLC Announces That Initial Abstract for Presentation of CCM Study of RenalGuard(R) at ESC 2009 Has Been Published; Strong Preliminary Results Seen 2Health News:PLC Announces That Initial Abstract for Presentation of CCM Study of RenalGuard(R) at ESC 2009 Has Been Published; Strong Preliminary Results Seen 3Health News:PLC Announces That Initial Abstract for Presentation of CCM Study of RenalGuard(R) at ESC 2009 Has Been Published; Strong Preliminary Results Seen 4Health News:Jani-King Recognized as Best in Support by the International Business Awards 2Health News:Moszkito(R) Expands its Archy(TM) Footwear Collection to Include Closed-Toed Shoes for Fall 2009 2Health News:American Medical Association Launches e-Book Strategy with iPublishCentral from Impelsys 2Health News:American Medical Association Launches e-Book Strategy with iPublishCentral from Impelsys 3
... Sunglasses collection benefits from innovative research in ... sectors such as the aerospace and automotive ... field and the footwear and textile industry. ... reinvented in the Carrera sunglasses collection to ...
Bottega Venetas new collection expresses a unique style and determined personality: discreet elegance and refined luxury are the themes that inspire the creation of these new models, destined to beco...
The new Stella McCartney sunglasses collection seduces with its sensual appeal and vintage spirit.,Bold patterned finishes, glamourous colour combinations and intricate details make the designers,cre...
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
Medicine Products: